Drugs / 177Lu-LNC1004
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06898437 | Mar 2025 → Mar 2026 overdue | differentiated thyroid carcinoma | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05723640 | Oct 2023 → Sep 2024 | cancer | Yantai LNC Biotechnology Singapore PTE. LTD. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-01-17 | SOFIE | Regulatory IND granted for FAP targeting therapeutic in SOFIE partnership sofie.com ↗
On Jan 6 th , 2023 Yantai LNC Biotechnology received FDA clearance to proceed with a Phase 1 clinical study of 177 Lu-LNC1004 injection, targeting fibroblast activation protein (FAP). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-01-17 | SOFIE | IND granted for FAP targeting therapeutic in SOFIE partnership sofie.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-LNC1004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05723640 ↗ |
| Modality | Other / unclassified | “177Lu-LNC1004 Injection group 1 radionuclide therapy” NCT05723640 ↗ |
| Route | Intravenous | “30mCi intravenous administration of 177Lu-LNC1004 Injection” NCT05723640 ↗ |
| Target | FAP | “a radiopharmaceutical targeting FAP” NCT06898437 ↗ |